ENEXIS is the first institutional investor in the European cannabis industry, focusing on minority investments in privately held companies. The Company’s founders, David Bonnier and Amaury de Poret, have over 40 years of combined experience in the finance and investment industry. Since the Company’s establishment in 2018, ENEXIS has reviewed over 250 companies in the legal cannabis sector and built a diversified portfolio of investments across the entire value chain, building at the same time a well-established network and a deep understanding of the nascent legal cannabis industry in Europe.

Through the listing, Enexis aims to provide retail investors with the opportunity to gain a diversified exposure to the legal cannabis market primarily in Europe. The market is expected to grow significantly in the coming years with clear legalization trends.[1] In connection to the listing the Company intends to carry out a new issue of B-shares (the “Offering”), in order to continue to create shareholder value by capitalizing on new attractive investment opportunities.

David Bonnier, co-founder and CEO, comments:
We look forward to offering access to an industry that’s at the early stages of a multi-decade structural growth curve, and supporting health and wellness companies that will help improve the quality of life for millions of patients.

Amaury de Poret, co-founder and Board member, comments:
We are very excited to bring to retail investors the possibility to get a regulatory-compliant and diversified exposure to an industry that is not only crisis-resilient and fast-growing, but also otherwise difficult to access.

Nordic offering
The Offering is intended to be announced in the second quarter of 2022 and is planned to be directed to the public in Sweden, Denmark, Finland, and Norway. The full terms of the Offering will be included in the EU Growth Prospectus to be published by the Company in connection to the Offering and then be available on the Company’s website, www.enexis.se.

Portfolio overview
ENEXIS portfolio consists of 19 holdings. Additional information about the portfolio holdings, net asset value and other KPI’s will be made public in connection with the Offering.

Strengths and competitive advantages

• Unique exposure to the European legal cannabis industry, a crisis-resilient market which is expected to grow significantly in the coming years.
• First institutional investor within the cannabis industry in Europe, with an unparalleled network and deep understanding of the nascent cannabis industry.
• Strong track record in terms of value growth, with a well-diversified portfolio of private minority investments offering exposure to the entire cannabis value chain.
• Market characterized by clear catalysts: continued legalization, political support and increased R&D are driving the growth in the medical cannabis sector, providing the base for the launching of a recreational market in Europe.

Advisers
Augment Partners AB is the financial advisor and Advokatfirman Vinge KB is the legal advisor in connection to the listing and the Offering. Nordnet Bank AB acts as the Selling Agent in Sweden, Denmark, Finland, and Norway in connection to the Offering.

For additional information, please contact:
David Bonnier, CEO, db@enexis.se, +46 (0)70 978 64 40

ENEXIS Certified Adviser is Augment Partners AB, info@augment.se, +46 (0)8 604 22 55

About ENEXIS
ENEXIS is an investment company focusing on the European legal cannabis and plant-based industries, mainly in the wellness and healthcare sectors. The Company’s main investment strategy is to take minority stakes in privately-held companies. More information is available on www.enexis.se.

Important information
This announcement is not for publication, distribution or release, directly or indirectly, in or into the United States of America (including its territories and possessions), Australia, Canada, Japan or any other jurisdiction where such an announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement is not an offer of securities or investments for sale nor a solicitation of an offer to buy securities or investments in any jurisdiction where such offer or solicitation would be unlawful. No action has been taken that would permit an offering of the securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions. The shares may not be offered to the public in any jurisdiction in circumstances which would require the preparation or registration of any prospectus or offering document relating to the shares in such jurisdiction. No action has been taken by the Company that would permit an offering of the shares or possession or distribution of this announcement or any other offering or publicity material relating to such securities in any jurisdiction where action for that purpose is required.

The shares referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered or sold in the United States (as defined in Regulation S under the Securities Act), except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws. Neither this document nor the information contained herein constitutes or forms part of an offer to sell or the solicitation of an offer to buy securities in the United States. There will be no public offer of any securities in the United States.

In member states of the European Economic Area (“EEA”) (each, a “Relevant Member State”), this announcement and any offer if made subsequently is directed exclusively at persons who are ‘qualified investors’ within the meaning of the Prospectus Regulation (“Qualified Investors”). For these purposes, the expression ‘Prospectus Regulation’ means Regulation (EU) 2017/1129. In the United Kingdom, this announcement is directed exclusively at persons who are ‘qualified ‘qualified investors’ within the meaning of the UK Prospectus Regulation and (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) who fall within Article 49(2)(A) to (D) of the Order, or (iii) to whom it may otherwise lawfully be communicated. For these purposes, the expression ‘UK Prospectus Regulation’ means Regulation (EU) 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.

[1] Prohibition Partners, The European Cannabis Report (2021).